$GH

FDA approves VEPPANU, first PROTAC therapy for advanced breast cancer with ESR1 mutations, showing 43% reduction in disease progression risk versus existing treatment.

Global oncology biomarkers market projected to grow from $17.3B (2025) to $33.63B (2030) at 14.3% CAGR, driven by AI, liquid biopsies, and precision medicine adoption.

$PRAX surges 685% annually, securing $80.5M from Driehaus Capital. Two FDA applications pending for neurological therapies with potential $20B+ revenue.